Study #2024-0162
A phase 3, randomized study of adjuvant Cretostimogene Grenadenorepvec versus observation for the treatment of intermediate risk non-muscle invasive bladder cancer (IR-NMIBC) following transurethral resection of bladder tumor (TURBT)
MD Anderson Study Status
Enrolling
Treatment Agent
Cretostimogene Grenadenorepvec
Description
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the treatment of participants with IR-NMIBC.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Study phase:
Phase III
Physician name:
Kelly Bree
Department:
Urology
For general questions about clinical trials:
1-855-982-0789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.